Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...